FR24C1025I1 - COMPOSITIONS AND METHODS OF TREATMENT OF ANEMIA - Google Patents
- ️Fri Jul 26 2024
US3655679A
(en)
1969-06-25
1972-04-11
Merck & Co Inc
Certain aryl pyridine carboxylic acid derivatives
US3703582A
(en)
1970-04-20
1972-11-21
Merck & Co Inc
Aryl pyridine carboxylic acids in the treatment of inflammation
US3894920A
(en)
1971-12-21
1975-07-15
Sagami Chem Res
Process for preparing alkyl-substituted 3,6-dihydro-o-dioxin derivatives
US4016287A
(en)
1972-07-17
1977-04-05
Boehringer Ingelheim Gmbh
Dermatological compositions containing an acylamino-carboxylic acid or an alkyl ester thereof
CA1261335A
(en)
1984-08-29
1989-09-26
Hoffmann-La Roche Limited/Hoffmann-La Roche Limitee
Ethylenediamine monoamide derivatives
CN1023479C
(en)
1985-09-27
1994-01-12
弗·哈夫曼-拉罗切有限公司
Preparation method of monoamide derivative of ethylenediamine
TW219933B
(en)
1990-02-26
1994-02-01
Lilly Co Eli
US5405613A
(en)
1991-12-11
1995-04-11
Creative Nutrition Canada Corp.
Vitamin/mineral composition
TW352384B
(en)
1992-03-24
1999-02-11
Hoechst Ag
Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals
DE4219158A1
(en)
1992-06-11
1993-12-16
Thomae Gmbh Dr K
Biphenyl derivatives, pharmaceutical compositions containing them and processes for their preparation
ES2101421T3
(en)
1993-11-02
1997-07-01
Hoechst Ag
SUBSTITUTED HETERO-CYCLIC CARBOXYLIC ACID AMIDES, THEIR PREPARATION AND THEIR USE AS MEDICINES.
DE59401923D1
(en)
1993-11-02
1997-04-10
Hoechst Ag
Substituted heterocyclic carboxylic acid amide esters, their preparation and their use as medicaments
TW406076B
(en)
1993-12-30
2000-09-21
Hoechst Ag
Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals
DE4410480A1
(en)
1994-03-25
1995-09-28
Hoechst Ag
Sulfonamidocarbonylpyridine-2-carboxylic acid ester amides and their pyridine N-oxides, processes for their preparation and their use as medicaments
DE4410423A1
(en)
1994-03-25
1995-09-28
Hoechst Ag
Sulfonamidocarbonylpyridin-2-carboxamides and their pyridine N-oxides, processes for their preparation and their use as medicaments
US5789426A
(en)
1995-01-20
1998-08-04
Cornell Research Foundation, Inc.
Method for the treatment of fibroproliferative disorders by application of inhibitors of protein hydroxylation
DE19535571A1
(en)
1995-09-14
1997-03-20
Boehringer Mannheim Gmbh
Combined pharmaceutical preparations and their use for the treatment of hemodialysis patients
IL135495A
(en)
1995-09-28
2002-12-01
Hoechst Ag
Intermediate compounds for the preparation of substituted quinoline-2-carboxylic acid amides
JPH09221476A
(en)
1995-12-15
1997-08-26
Otsuka Pharmaceut Co Ltd
Medicinal composition
AU5762896A
(en)
1996-04-30
1997-11-19
Hoechst Aktiengesellschaft
3-alkoxypyridine-2-carboxylic acid amide esters, their preparation and the ir use as drugs
DE19620041A1
(en)
1996-05-17
1998-01-29
Merck Patent Gmbh
Adhesion receptor antagonists
DE19650215A1
(en)
1996-12-04
1998-06-10
Hoechst Ag
3-hydroxypyridine-2-carboxylic acid amide esters, their preparation and their use as medicaments
CN1282319A
(en)
1997-10-09
2001-01-31
小野药品工业株式会社
Aminobutanoic acid derivatives
DE19746287A1
(en)
1997-10-20
1999-04-22
Hoechst Marion Roussel De Gmbh
Substituted isoquinoline-2-carboxylic acid amides, their preparation and their use as medicaments
CN1297440A
(en)
1998-03-23
2001-05-30
阿温蒂斯药物制品公司
Piperidinyl and N-amidinopiperidinyl derivs.
GB9809213D0
(en)
1998-04-29
1998-07-01
Glaxo Group Ltd
Pharmaceutical compositions
PT1083885E
(en)
1998-06-11
2007-01-31
Pharmacia & Upjohn Co Llc
Delavirdine tablet formulation
US6159379A
(en)
1999-05-04
2000-12-12
Baker Hughes Incorporated
Organic ammonium salts for the removal of water soluble organics in produced water
JP2001048786A
(en)
1999-08-05
2001-02-20
Yamanouchi Pharmaceut Co Ltd
Tricyclic heteroaryl derivative
US6589758B1
(en)
2000-05-19
2003-07-08
Amgen Inc.
Crystal of a kinase-ligand complex and methods of use
ATE508738T1
(en)
2001-01-12
2011-05-15
Sun Pharma Advanced Res Co Ltd
SYSTEM FOR THE DISTANCED DELIVERY OF MEDICINAL PRODUCTS
US6855510B2
(en)
2001-03-20
2005-02-15
Dana Farber Cancer Institute, Inc.
Pharmaceuticals and methods for treating hypoxia and screening methods therefor
US6849718B2
(en)
2001-03-20
2005-02-01
Dana Farber Cancer Institute, Inc.
Muteins of hypoxia inducible factor alpha and methods of use thereof
WO2002074981A2
(en)
2001-03-21
2002-09-26
Isis Innovation Ltd.
Assays, methods and means relating to hypoxia inducible factor (hif) hydroxylase
SE0101327D0
(en)
2001-04-12
2001-04-12
Astrazeneca Ab
New crystalline forms
US6566088B1
(en)
2001-10-04
2003-05-20
Board Of Regents, The University Of Texas System
Prolyl-4-hydroxylases
GB0124941D0
(en)
2001-10-17
2001-12-05
Glaxo Group Ltd
Chemical compounds
EP2289531B1
(en)
*
2001-12-06
2018-07-04
Fibrogen, Inc.
Medicaments for the treatment or prevention of anemia
CA2486141A1
(en)
2002-05-17
2003-11-27
Celgene Corporation
Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
US7157100B2
(en)
*
2002-06-04
2007-01-02
J.B. Chemicals & Pharmaceuticals Ltd.
Pharmaceutical composition for controlled drug delivery system
RU2005108667A
(en)
2002-08-29
2005-08-27
Мерк энд Ко., Инк. (US)
N-BIARILMETHYLAMINOCYCLOCALACANBOXAMIDE DERIVATIVES
CA2502541A1
(en)
2002-10-16
2004-04-29
Isis Innovation Limited
Asparaginyl hydroxylases and modulators thereof
CA2506799A1
(en)
2002-11-21
2004-06-10
Eli Lilly And Company
Mixed lineage kinase modulators
US8124582B2
(en)
2002-12-06
2012-02-28
Fibrogen, Inc.
Treatment of diabetes
US7618940B2
(en)
2002-12-06
2009-11-17
Fibrogen, Inc.
Fat regulation
US7183287B2
(en)
2003-04-03
2007-02-27
Pharmacia Corporation
Substituted pyrimidinones
US20060251638A1
(en)
2003-06-06
2006-11-09
Volkmar Guenzler-Pukall
Cytoprotection through the use of hif hydroxylase inhibitors
US8614204B2
(en)
2003-06-06
2013-12-24
Fibrogen, Inc.
Enhanced erythropoiesis and iron metabolism
CN1816527A
(en)
2003-06-06
2006-08-09
菲布罗根有限公司
Nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin
GB0314129D0
(en)
2003-06-18
2003-07-23
Astrazeneca Ab
Therapeutic agents
EP1766047B1
(en)
2004-05-28
2009-09-23
Fibrogen, Inc.
Hif prolyl hydroxylase activity assay
WO2005115984A2
(en)
2004-05-31
2005-12-08
Tanabe Seiyaku Co., Ltd.
Large conductance calcium-activitated k channel opener
KR20070083484A
(en)
2004-07-14
2007-08-24
피티씨 테라퓨틱스, 인크.
How to Treat Hepatitis C
TW200616969A
(en)
2004-09-17
2006-06-01
Tanabe Seiyaku Co
Imidazole compound
WO2006084210A2
(en)
2005-02-04
2006-08-10
Regents Of The University Of California, San Diego
Hif modulating compounds and methods of use thereof
DE102005019712A1
(en)
2005-04-28
2006-11-09
Bayer Healthcare Ag
Dipyridyl-dihydropyrazolone and its use
CN101394843A
(en)
2005-06-06
2009-03-25
菲布罗根公司
Improved treatment for anemia using a HIF-alpha stabilising agent
CA2611785A1
(en)
2005-06-15
2006-12-28
Fibrogen, Inc.
Use of hif 1alfa modulators for treatment of cancer
RU2424805C2
(en)
2005-09-12
2011-07-27
Актелион Фармасьютиклз Лтд
Stable pharmaceutical pyrimidinsulfamide-including compositions
WO2007033216A2
(en)
2005-09-12
2007-03-22
Beth Israel Deaconess Medical Center
Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
WO2007038571A2
(en)
2005-09-26
2007-04-05
Smithkline Beecham Corporation
Prolyl hydroxylase antagonists
WO2007047194A2
(en)
2005-10-11
2007-04-26
Dana-Farber Cancer Institute, Inc.
Methods for treating mitf-related disorders
ES2446416T3
(en)
2005-12-09
2014-03-07
Amgen, Inc.
Quinolone-based compounds that have prolyl hydroxylase inhibitory activity, compositions and uses thereof
US20090023666A1
(en)
2006-01-09
2009-01-22
BTG plc
Modulators of Hypoxia Inducible Factor-1 and Related Uses
EP1983823A1
(en)
2006-01-17
2008-10-29
VIB vzw
Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration
TW200738709A
(en)
2006-01-19
2007-10-16
Osi Pharm Inc
Fused heterobicyclic kinase inhibitors
JP4801451B2
(en)
2006-01-19
2011-10-26
株式会社日立ハイテクノロジーズ
Control device and control method for electron gun used in scanning electron microscope and the like
ITMI20060179A1
(en)
2006-02-02
2007-08-03
Abiogen Pharma Spa
PROCEDURE FOR RESOLUTION OF RACEMIC MIXTURES AND DIASTEREOISOMERIC COMPLEX OF A SOLVING AGENT AND UNANTIOMER OF INTEREST
WO2007101204A1
(en)
2006-02-27
2007-09-07
Alcon Research, Ltd.
Method of treating glaucoma
US7588924B2
(en)
2006-03-07
2009-09-15
Procter & Gamble Company
Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
AR059733A1
(en)
2006-03-07
2008-04-23
Smithkline Beecham Corp
COMPOSITE DERIVED FROM GLYCIN N- REPLACED WITH BICYCLE HETEROAROMATICS, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, USE TO PREPARE A MEDICINAL PRODUCT TO TREAT ANEMIA AND PROCESS FOR PREPARATION
US20090176825A1
(en)
2006-05-16
2009-07-09
Fitch Duke M
Prolyl hydroxylase inhibitors
KR100798730B1
(en)
*
2006-06-12
2008-01-29
신풍제약주식회사
Controlled-release preparations containing roxofene or zaltoprofen and preparation methods thereof
PE20080209A1
(en)
2006-06-23
2008-05-15
Smithkline Beecham Corp
GLYCINE DERIVATIVES AS PROLYL HYDROXYLASE INHIBITORS
ES2705587T3
(en)
2006-06-26
2019-03-26
Akebia Therapeutics Inc
Prolyl hydroxylase inhibitors and methods of use
CA2563690C
(en)
2006-10-12
2014-10-07
Pharmascience Inc.
Pharmaceutical compositions comprising intra- and extra- granular fractions
IES20070122A2
(en)
2006-12-05
2008-05-28
Michael Hilary Burke
A process for the preparation of an orally administered unit dose tablet
TW200845991A
(en)
2007-01-12
2008-12-01
Smithkline Beecham Corp
N-substituted glycine derivatives: hydroxylase inhibitors
TW200845994A
(en)
2007-01-12
2008-12-01
Smithkline Beecham Corp
N-substituted glycine derivatives: prolyl hydroxylase inhibitors
WO2008125388A1
(en)
2007-04-17
2008-10-23
Ratiopharm Gmbh
Pharmaceutical compositions comprising irbesartan
US7569726B2
(en)
2007-04-18
2009-08-04
Amgen Inc.
Indanone derivatives that inhibit prolyl hydroxylase
WO2008130527A1
(en)
2007-04-18
2008-10-30
Merck & Co., Inc.
Novel 1,8-naphthyridine compounds
WO2008137060A1
(en)
2007-05-04
2008-11-13
Amgen Inc.
Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity
US8309544B2
(en)
2007-05-16
2012-11-13
Merck Sharp & Dohme Corp.
Spiroindalones
AU2008253311A1
(en)
2007-05-18
2008-11-27
Bayer Schering Pharma Aktiengesellshaft
Inhibitors of hypoxia inducible factor (HIF) useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
EP2186528B1
(en)
2007-08-06
2014-03-19
Senju Pharmaceutical Co., Ltd.
Pharmaceutical containing hif-1 alpha and hif-2 alpha expression inhibitor
TW200908984A
(en)
2007-08-07
2009-03-01
Piramal Life Sciences Ltd
Pyridyl derivatives, their preparation and use
JP2010535855A
(en)
2007-08-10
2010-11-25
クリスタルゲノミクス、インク．
Pyridine derivatives and methods of use thereof
WO2009035534A2
(en)
2007-09-07
2009-03-19
The Cleveland Clinic Foundation
Treatment of ischemic eye disease by the systematic pharmaceutical activation of hypoxia inducible factor (hif)
WO2009039323A1
(en)
2007-09-19
2009-03-26
Smithkline Beecham Corporation
Prolyl hydroxylase inhibitors
WO2009039321A1
(en)
2007-09-19
2009-03-26
Smithkline Beecham Corporation
Prolyl hydroxylase inhibitors
WO2009043093A1
(en)
2007-10-04
2009-04-09
Newsouth Innovations Pty Limited
Hif inhibition
WO2009049112A1
(en)
2007-10-10
2009-04-16
Smithkline Beecham Corporation
Prolyl hydroxylase inhibitors
WO2009067790A1
(en)
2007-11-26
2009-06-04
Uti Limited Partnership
STIMULATION OF HYPOXIA INDUCIBLE FACTOR -1 ALPHA (HIF-1α) FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASE (CDAD), FOR INTESTINAL MOTILITY AND FOR DETECTING INFECTION
NZ585701A
(en)
2007-11-30
2012-09-28
Glaxosmithkline Llc
Benzopyrazine derivatives as prolyl hydroxylase inhibitors
US20100305154A1
(en)
2007-11-30
2010-12-02
Glaxosmithkline Llc
Prolyl Hydroxylase Inhibitors
EP2227475B1
(en)
2007-12-03
2014-02-19
Fibrogen, Inc.
Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions
EP2240178A4
(en)
2007-12-19
2011-10-26
Glaxosmithkline Llc
Prolyl hydroxylase inhibitors
WO2009086592A1
(en)
2008-01-04
2009-07-16
Garvan Institute Of Medical Research
Method of increasing metabolism
US8952160B2
(en)
2008-01-11
2015-02-10
Fibrogen, Inc.
Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity
CA2716706C
(en)
2008-03-03
2014-02-18
Irm Llc
Compounds and compositions as tlr activity modulators
JP2011528686A
(en)
2008-07-23
2011-11-24
エフ．ホフマン−ラ ロシュ アーゲー
Heterocyclic antiviral compounds
TW201006473A
(en)
2008-08-13
2010-02-16
Orient Pharma Co Ltd
Bi-layer medicine tablet containing Zaleplon
EP2324006B1
(en)
2008-09-15
2014-08-13
Kasina Laila Innova Pharmaceuticals Private Ltd.
Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers
HU230877B1
(en)
*
2008-09-30
2018-11-29
EGIS Gyógyszergyár NyR
Stable combination medicine
US8927591B2
(en)
2008-11-14
2015-01-06
Fibrogen, Inc.
Thiochromene derivatives as HIF hydroxylase inhibitors
US8137666B2
(en)
*
2008-11-22
2012-03-20
Academia Sinica
Nattokinase for degrading and reducing amyloid fibrils—associated with alzheimer's disease, prion diseases and other amyloidoses
PL2732818T3
(en)
2009-03-31
2017-12-29
Ligand Pharmaceuticals Inc.
A biphenylsulfonamide endothelin and angiotensin ii receptor antagonist to treat glomerulosclerosis
BRPI1013432B1
(en)
2009-03-31
2019-12-17
Kissei Pharmaceutical
derivative of indolizine and pharmaceutical composition
EP2746282A1
(en)
2009-07-17
2014-06-25
Japan Tobacco Inc.
Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor and erythropoietin production inducer
KR101591701B1
(en)
2009-11-06
2016-02-05
에르피오 세러퓨틱스 인코포레이티드
Methods for increasing the stabilization of hypoxia inducible factor-1 alpha
WO2012097331A1
(en)
2011-01-13
2012-07-19
Fibrogen, Inc.
Methods for increasing reticulocyte hemoglobin content
NO2686520T3
(en)
*
2011-06-06
2018-03-17
EP2717870B1
(en)
2011-06-06
2017-09-27
Akebia Therapeutics Inc.
Composition for stabilizing hypoxia inducible factor-2 alpha useful for treating cancer
US20130022974A1
(en)
2011-06-17
2013-01-24
The Regents Of The University Of Michigan
Dna methylation profiles in cancer
JP6099644B2
(en)
2011-07-22
2017-03-22
ベイジン ベータ ファーマシューティカルズ カンパニー， リミテッド
Polymorphs of compounds as prolyl hydroxylase inhibitors and uses thereof
US11491154B2
(en)
2013-04-08
2022-11-08
Dennis M. Brown
Therapeutic benefit of suboptimally administered chemical compounds
AU2014278543B2
(en)
*
2013-06-13
2019-11-14
Akebia Therapeutics, Inc.
Compositions and methods for treating anemia
MX2016002014A
(en)
2013-08-16
2016-07-21
Ohio State Innovation Foundation
Compositions and methods for modulating dna methylation.
RU2016123382A
(en)
2013-11-15
2017-12-20
Экебиа Терапьютикс, Инк.
SOLID FORMS {{5- (3-CHLOROPHENYL) -3-HYDROXYPYRIDIN-2-CARBONYL] AMINO} ACETIC ACID, THEIR COMPOSITION AND USE
MX2016009331A
(en)
2014-01-23
2016-10-26
Akebia Therapeutics Inc
Compositions and methods for treating ocular diseases.
WO2016118858A1
(en)
2015-01-23
2016-07-28
Akebia Therapeutics, Inc.
Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
EP3270922A4
(en)
2015-03-20
2018-08-01
Akebia Therapeutics Inc.
Deuterium-enriched hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors
ES2900481T3
(en)
2015-04-01
2022-03-17
Akebia Therapeutics Inc
Compositions and methods for treating anemia
WO2019028150A1
(en)
2017-08-01
2019-02-07
Akebia Therapeutics, Inc.
Compositions for use in methods of treatment of hemoglobin disorders
CN113382729A
(en)
2018-10-03
2021-09-10
阿克比治疗有限公司
Benzimidazole derivatives for the treatment of inflammatory disorders
US11524939B2
(en)
*
2019-11-13
2022-12-13
Akebia Therapeutics, Inc.
Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid